CIBC Asset Management Inc Buys 788 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

CIBC Asset Management Inc grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.1% in the fourth quarter, HoldingsChannel.com reports. The fund owned 26,366 shares of the company’s stock after acquiring an additional 788 shares during the quarter. CIBC Asset Management Inc’s holdings in IDEXX Laboratories were worth $10,901,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. FSA Wealth Management LLC bought a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. lifted its position in shares of IDEXX Laboratories by 5,700.0% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after acquiring an additional 57 shares during the period. Mowery & Schoenfeld Wealth Management LLC lifted its position in shares of IDEXX Laboratories by 750.0% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock valued at $34,000 after acquiring an additional 60 shares during the period. Ashton Thomas Securities LLC bought a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at $37,000. Finally, Retirement Wealth Solutions LLC bought a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $31,000. 87.84% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on IDXX shares. Morgan Stanley dropped their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. Leerink Partners started coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price objective for the company. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, February 5th. Finally, Bank of America upped their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $533.75.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $449.06 on Wednesday. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39. The business has a 50-day simple moving average of $430.82 and a two-hundred day simple moving average of $452.56. The company has a quick ratio of 1.03, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The stock has a market cap of $36.77 billion, a PE ratio of 42.09, a PEG ratio of 3.47 and a beta of 1.37.

Insider Activity

In other news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the sale, the director now owns 905 shares of the company’s stock, valued at approximately $380,498.20. This represents a 27.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 13,330 shares of company stock valued at $6,161,276. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.